CFLAR

Migration, Crosslink

📖

CFLAR

active

wiki page Created: 2026-04-02T07:19:27 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-cflar

📖 Wiki Page

gene2704 wordssynced 2026-04-02

CFLAR

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CFLAR</th>
</tr>
<tr>
<td class="label">Full Name</td>
<td>CASP8 and FADD-like apoptosis regulator</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CFLAR</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>c-FLIP, FLIP, Usurpin</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>2q33.1</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein-coding</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[603598](https://omim.org/entry/603598)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>[O15519](https://www.uniprot.org/uniprot/O15519)</td>
</tr>
<tr>
<td class="label">HGNC</td>
<td>[8866](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8866)</td>
</tr>
<tr>
<td class="label">Entrez Gene</td>
<td>[8837](https://www.ncbi.nlm.nih.gov/gene/8837)</td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td>[ENSG00000003402](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000003402)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">27 edges</a></td>
</tr>
</table>

CFLAR (c-FLIP)

...

CFLAR

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CFLAR</th>
</tr>
<tr>
<td class="label">Full Name</td>
<td>CASP8 and FADD-like apoptosis regulator</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CFLAR</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>c-FLIP, FLIP, Usurpin</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>2q33.1</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein-coding</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[603598](https://omim.org/entry/603598)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>[O15519](https://www.uniprot.org/uniprot/O15519)</td>
</tr>
<tr>
<td class="label">HGNC</td>
<td>[8866](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8866)</td>
</tr>
<tr>
<td class="label">Entrez Gene</td>
<td>[8837](https://www.ncbi.nlm.nih.gov/gene/8837)</td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td>[ENSG00000003402](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000003402)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">27 edges</a></td>
</tr>
</table>

CFLAR (c-FLIP)

</div>

Overview

CFLAR (CASP8 and FADD-like apoptosis regulator), most commonly known by its protein product c-FLIP (cellular FLICE-inhibitory protein), is a critical molecular regulator of programmed cell death pathways. Located on chromosome 2q33.1, CFLAR encodes a protein that plays a pivotal role in determining cell fate decisions between survival and death in response to external cellular signals[@thoma1999].

c-FLIP functions as a master regulator of the extrinsic [apoptosis](/mechanisms/apoptosis) pathway by competitively inhibiting caspase-8 activation at the death-inducing signaling complex (DISC). Beyond its well-characterized anti-apoptotic function, c-FLIP also regulates [necroptosis](/mechanisms/necroptosis) and influences intrinsic mitochondrial apoptosis pathways, making it a central node in cell death signaling networks[@sprick2000].

In the context of neurodegenerative diseases, c-FLIP has emerged as a significant player in determining neuronal survival or death in Alzheimer's disease and Parkinson's disease. The balance between pro-survival and pro-death signaling in neurons is critical for maintaining proper neuronal populations, and CFLAR expression levels influence neuronal vulnerability to toxic stimuli associated with disease pathogenesis[@obu2012].

Gene and Protein Structure

Gene Organization

The CFLAR gene spans approximately 35 kb and encodes multiple protein isoforms through alternative splicing. The gene contains 13 exons and produces several distinct mRNA variants that give rise to protein isoforms with different functional properties.

Protein Isoforms

c-FLIP exists in multiple isoforms, each with distinct functions:

c-FLIP_L (Long isoform): Approximately 55 kDa, contains two Death Effector Domains (DEDs) and a caspase-like domain. While primarily anti-apoptotic, the long isoform can also exhibit pro-apoptotic functions under certain conditions[@ye2001].

c-FLIP_S (Short isoform): Approximately 26 kDa, contains only the two DEDs. This isoform is exclusively anti-apoptotic and acts as a dominant inhibitor of caspase-8 activation[@hacker2009].

c-FLIP_R (Rare isoform): A minor isoform with intermediate properties.

The structural organization of c-FLIP mirrors that of caspase-8, with the DEDs at the N-terminus being responsible for DED-mediated protein interactions, including recruitment to the DISC and competitive inhibition of caspase-8.

Structure-Function Relationships

The DEDs of c-FLIP mediate interactions with:

FADD (Fas-associated via death domain): Essential adaptor protein for death receptor signaling
Caspase-8: The target protease that c-FLIP inhibits
Other DED-containing proteins: Regulatory network interactions

The caspase-like domain in c-FLIP_L, while enzymatically inactive, can interfere with caspase-8 processing and activation through allosteric mechanisms.

Normal Function

Death Receptor Signaling

The primary function of c-FLIP is regulating signaling through death receptors of the TNF receptor superfamily. Key death receptors include:

Fas (CD95): Mediates apoptosis in response to Fas ligand
TNF receptor 1 (TNFR1): Can trigger apoptosis, necroptosis, or survival depending on context
DR4/TRAIL-R1 and DR5/TRAIL-R2: Bind TRAIL and induce apoptosis

Upon ligand binding, death receptors oligomerize and recruit adaptor proteins including FADD, which then recruits procaspase-8. The assembled complex, known as the DISC (death-inducing signaling complex), is where caspase-8 activation occurs. c-FLIP competes with caspase-8 for binding to FADD, thereby regulating the magnitude of caspase-8 activation and downstream apoptosis signaling[@sprick2000].

NF-κB Regulation

c-FLIP expression is itself regulated by NF-κB, creating a feedback loop that links survival signaling with death receptor pathways. NF-κB activation induces CFLAR transcription, and the resulting c-FLIP protein can then inhibit caspase-8 activation at the DISC while simultaneously allowing NF-κB signaling to proceed[@micheau2001].

This dual function makes c-FLIP a critical determinant of whether death receptor activation leads to apoptosis or survival. In cells with high c-FLIP expression, death receptor engagement may preferentially activate NF-κB and survival pathways rather than apoptosis.

Regulation of Necroptosis

Beyond apoptosis, c-FLIP also regulates necroptosis, a form of programmed necrosis. Necroptosis is mediated by the RIPK1-RIPK3-MLKL axis, and caspase-8 can cleave and inactivate RIPK1 and RIPK3, thereby preventing necroptosis. By inhibiting caspase-8, c-FLIP can indirectly promote necroptosis under certain conditions.

The balance between apoptosis and necroptosis has significant implications for disease pathogenesis, as these different cell death modalities have distinct inflammatory consequences. Apoptosis is immunologically silent, while necroptosis releases intracellular contents and triggers inflammatory responses.

Expression in the Brain

Neuronal Expression Patterns

CFLAR is widely expressed throughout the central nervous system with particularly high levels in:

Cerebral cortex: Pyramidal neurons in layers 2-6
Hippocampus: CA1-CA3 pyramidal cells and dentate gyrus granule neurons
Cerebellum: Purkinje cells and granule cells
Basal ganglia: Medium spiny neurons in the striatum

At the subcellular level, c-FLIP localizes to both cytoplasmic and membrane-associated compartments, consistent with its role in regulating DISC assembly at the plasma membrane.

Regulation in Neurons

Neuronal c-FLIP expression is dynamically regulated by:

NF-κB activation: Pro-inflammatory cytokines increase CFLAR expression
Activity-dependent signaling: Neuronal activity can modulate c-FLIP levels
Stress responses: Various cellular stresses alter c-FLIP expression

The regulation of c-FLIP in neurons is particularly relevant to neurodegenerative diseases, where inflammatory responses and cellular stress are prominent features.

Disease Associations

Alzheimer's Disease

c-FLIP has emerged as a significant player in Alzheimer's disease pathogenesis through multiple mechanisms:

Neuronal Survival: Elevated c-FLIP expression may protect neurons from apoptosis in AD. Studies show that c-FLIP levels are increased in AD brain tissue, potentially as a compensatory neuroprotective response to disease pathology. The anti-apoptotic function of c-FLIP could serve to delay neuronal loss during disease progression[@obu2012].

Amyloid-Beta Interaction: [Amyloid-beta](/proteins/amyloid-beta) peptide, the pathogenic driver of AD, can influence c-FLIP expression and function. In cellular models, amyloid-beta treatment modulates CFLAR expression, with complex effects on cell survival pathways[@zhang2018].

Tau Pathology: Hyperphosphorylated [tau](/proteins/tau) protein, which forms neurofibrillary tangles in AD, interacts with c-FLIP regulatory pathways. The relationship between tau pathology and c-FLIP suggests that c-FLIP may influence the progression of tau-mediated neurodegeneration[@zhou2022].

Therapeutic Implications: Modulating c-FLIP expression or function represents a potential therapeutic strategy for AD. The goal would be to enhance the neuroprotective effects of c-FLIP while avoiding potential adverse effects on other cellular processes[@morin2019].

Parkinson's Disease

In Parkinson's disease, c-FLIP plays relevant roles in determining dopaminergic neuron survival:

Dopaminergic Neuron Vulnerability: c-FLIP expression in dopaminergic neurons influences their susceptibility to various toxic stimuli relevant to PD pathogenesis, including oxidative stress and mitochondrial dysfunction[@kokai2019].

Death Receptor Pathways: TRAIL-mediated signaling, regulated by c-FLIP, may contribute to dopaminergic neuron death in PD models. The balance between c-FLIP and pro-apoptotic regulators determines whether death receptor activation triggers apoptosis or survival.

Neuroinflammation: The interaction between neuroinflammation and c-FLIP regulation is particularly relevant to PD, as microglial activation and inflammatory cytokine production can modulate neuronal c-FLIP expression.

Genetic Associations: Polymorphisms in the CFLAR gene have been associated with modified risk for Parkinson's disease, though the functional significance of these variants continues to be investigated[@liu2021].

Cancer (Dual Role)

CFLAR exhibits a dual role in cancer biology:

Oncogenic Function: Elevated c-FLIP expression is common in many cancer types, where it confers resistance to death receptor-mediated apoptosis. High c-FLIP levels in tumor cells can protect them from immune surveillance and chemotherapy-induced cell death[@wang2007].

Therapeutic Target: Targeting c-FLIP in cancer is an active area of research, with strategies including:

Direct c-FLIP inhibitors
Agents that downregulate CFLAR expression
Combinatorial approaches with TRAIL-based therapies

The context-dependent nature of c-FLIP function makes it a challenging but potentially valuable therapeutic target.

Neurodevelopmental and Psychiatric Disorders

CFLAR has been implicated in several other conditions:

Developmental Cell Death: During brain development, appropriate levels of programmed cell death are essential for proper neural circuit formation. CFLAR regulates developmental apoptosis in neural progenitor populations[@kirkbride2011].

Mood Disorders: Altered c-FLIP expression has been reported in some psychiatric conditions, though the significance remains under investigation.

Mechanisms in Neurodegeneration

Apoptosis Inhibition

The primary mechanism by which c-FLIP influences neurodegeneration is through inhibition of caspase-8-mediated extrinsic apoptosis. In neurons, this pathway is relevant to:

Death receptor activation: Including Fas, TRAIL receptors, and TNFR1
Excitotoxicity: Glutamate-induced toxicity involves death receptor signaling
Oxidative stress: Reactive oxygen species can activate death receptor pathways

By inhibiting caspase-8 activation, c-FLIP prevents the initiation of the caspase cascade that leads to apoptotic cell death.

Cross-Talk with Mitochondrial Apoptosis

c-FLIP interacts with intrinsic apoptosis pathways through multiple mechanisms:

Caspase-8 activation can trigger the mitochondrial apoptosis pathway through Bid cleavage
c-FLIP isoforms differentially affect this cross-talk
Survival signaling through NF-κB can promote expression of anti-apoptotic Bcl-2 family proteins[@song2017]

Neuroinflammation

c-FLIP plays roles in neuroinflammation through:

Microglial activation: c-FLIP regulates inflammatory responses in microglia
Cytokine signaling: NF-κB-dependent CFLAR expression affects inflammatory cascades
Neuroinflammatory diseases: c-FLIP dysregulation contributes to chronic neuroinflammation[@ju2019]

TRAIL Signaling

TNF-related apoptosis-inducing ligand (TRAIL) is particularly relevant to neurodegeneration:

TRAIL receptors are expressed in neurons
TRAIL-mediated apoptosis is regulated by c-FLIP
TRAIL signaling may contribute to neuronal loss in AD and PD[@yang2020]

Therapeutic Approaches

Targeting c-FLIP in Neurodegeneration

Several strategies for modulating c-FLIP in neurodegenerative diseases are under investigation:

Enhancing c-FLIP Expression: Pharmacological approaches to increase c-FLIP levels could enhance neuronal survival. NF-κB activators and other agents that upregulate CFLAR transcription are being explored.

Stabilizing c-FLIP Protein: Preventing c-FLIP degradation could maintain its anti-apoptotic function. Proteasome inhibitors that prevent c-FLIP degradation have shown neuroprotective effects in some models.

Modulating c-FLIP Isoforms: The balance between c-FLIP_L and c-FLIP_S isoforms has different functional consequences. Selective modulation of isoform expression could provide therapeutic benefit.

Challenges and Considerations

Several challenges must be addressed:

Safety: Global enhancement of c-FLIP could interfere with tumor surveillance and normal immune function
Specificity: Targeting neuronal c-FLIP specifically in the brain is technically challenging
Isoform Complexity: The different c-FLIP isoforms have complex and sometimes opposing functions
Context Dependence: The effects of c-FLIP modulation depend on cellular context and disease stage

Biomarker Potential

c-FLIP expression in peripheral blood cells or cerebrospinal fluid may serve as a biomarker for:

Disease progression in AD and PD
Treatment response to neuroprotective therapies
Neuronal injury and death

Research Methods

The study of CFLAR in neurodegeneration employs various approaches:

Biochemistry: Analysis of c-FLIP protein levels and modifications
Cell biology: Cell culture models of neuronal death and survival
Mouse models: Genetic and pharmacological manipulation of Cflar
Human tissue: Analysis of CFLAR expression in post-mortem brain
Clinical studies: CFLAR as biomarker and therapeutic target

Clinical Perspectives

Diagnostic and Therapeutic Considerations

The clinical management of CFLAR-related pathways in neurodegeneration requires careful consideration:

Diagnostic biomarkers: While direct CFLAR testing is not routine in neurodegenerative disease diagnosis, components of the death receptor pathway can be measured in research settings. Elevated soluble TRAIL receptors (sTRAIL-R1, sTRAIL-R2) in CSF have been explored as markers of death receptor activation in AD and PD.

Therapeutic targeting considerations: Modulating the CFLAR pathway requires balancing neuroprotective effects against potential risks:

Cancer surveillance: c-FLIP levels must be maintained for immune surveillance against malignancies
Immune function: Death receptor pathways are involved in immune cell regulation
Tissue specificity: Brain-specific targeting remains challenging for small molecules

Disease-Stage Specific Effects

The role of c-FLIP may vary with disease stage:

Early disease: Upregulation of c-FLIP may represent a compensatory neuroprotective response, potentially delaying neuronal loss.

Advanced disease: c-FLIP dysregulation may contribute to impaired apoptosis and accumulation of damaged neurons.

Therapeutic implications: Timing of intervention may be critical - enhancing c-FLIP early may be beneficial, while later stages may require different approaches.

Animal Models

c-FLIP expression represents a promising biomarker candidate for neurodegenerative disease research:

Peripheral Biomarkers: Studies have examined CFLAR expression in peripheral blood mononuclear cells (PBMCs) from AD and PD patients. Altered c-FLIP levels have been reported in patient cohorts, though results vary by disease stage and patient population. The biomarker potential requires validation in larger longitudinal studies.

CSF Biomarkers: Cerebrospinal fluid c-FLIP measurement remains experimental. Challenges include low protein concentration and the blood-brain barrier as a barrier to CSF access of brain-derived c-FLIP.

Therapeutic Monitoring: c-FLIP modulators currently under development may require biomarker monitoring for treatment response assessment.

Clinical Implications

The dual nature of c-FLIP in both neuroprotection and cancer creates therapeutic complexity:

Oncological Contraindication: Any therapeutic targeting c-FLIP must carefully consider potential tumor-promoting effects, particularly in patients with history of malignancy or precancerous conditions.

Age Considerations: The role of c-FLIP in age-related neurodegeneration may differ between early-onset and late-onset disease forms.

Combination Therapies: c-FLIP modulators may have synergistic effects with other neuroprotective strategies, including anti-amyloid, anti-tau, and mitochondrial protective approaches.

Animal Models

Mouse Models

Cflar Knockout Mice: Complete Cflar knockout is embryonic lethal due to heart defects. Tissue-specific knockouts using neuronal promoters (Nestin-Cre, Camk2a-Cre) allow study of c-FLIP function in the nervous system. Neuron-specific knockout leads to increased apoptosis during development and enhanced sensitivity to excitotoxic injury[@barnhart2003].

Transgenic Overexpression: Neuronal overexpression of c-FLIP protects against various insults including:

Excitotoxicity (kainic acid models)
Cerebral ischemia
Mitochondrial toxins (MPTP, 6-OHDA)
Amyloid-beta toxicity

Disease Model Studies: Crossbreeding of Cflar transgenic mice with APP/PSEN1 or alpha-synuclein transgenic models reveals interactions between c-FLIP and disease pathology.

In Vitro Models

Primary Neuronal Cultures: c-FLIP function studied in:

Cortical neuron cultures
Hippocampal neurons
Mesencephalic dopaminergic neurons
Cerebellar granule neurons

iPSC-Derived Neurons: Patient-derived neurons carrying CFLAR variants enable study of disease-specific mutations and personalized medicine approaches.

Zebrafish Models

Zebrafish provide accessible models for studying c-FLIP during development. Morpholino knockdown of c-FlIP leads to developmental abnormalities, while overexpression protects against neuronal injury.

Interaction Networks

Protein-Protein Interactions

c-FLIP participates in multiple protein interaction networks:

Mermaid diagram (expand to render)

Genetic Interactions

CFLAR interacts with multiple genes implicated in neurodegeneration:

CASP8: Direct functional relationship as inhibitor
FADD: Co-factor in DISC formation
TNF: upstream activator of death receptor pathways
BCL2: cross-talk with mitochondrial apoptosis
RIPK1/RIPK3: regulation of necroptosis pathway

Future Research Directions

Unresolved Questions

Isoform-specific functions: The differential roles of c-FLIP_L and c-FLIP_S in neurons remain incompletely understood

Cell type specificity: How c-FLIP function differs between neuronal subtypes

Temporal dynamics: How c-FLIP expression changes during disease progression

Therapeutic window: Optimal timing and dosing for c-FLIP-targeted interventions

Emerging Approaches

Brain-penetrant small molecules: Development of BBB-permeant c-FLIP modulators

Gene therapy: AAV-mediated c-FLIP delivery to neurons

Combination strategies: Synergistic approaches with other neuroprotective agents

Personalized medicine: CFLAR genotyping to predict treatment response

External Links

[OMIM: 603598](https://omim.org/entry/603598)
[GeneCards: CFLAR](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CFLAR)
[UniProt: O15519](https://www.uniprot.org/uniprot/O15519)
[HGNC: CFLAR](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8866)
[NCBI Gene: CFLAR](https://www.ncbi.nlm.nih.gov/gene/8837)
[PubMed: CFLAR neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=CFLAR+neurodegeneration)

References

[Thoma et al., c-FLIP structure and function (1999)](https://pubmed.ncbi.nlm.nih.gov/10385527/)

[Barnhart et al., c-FLIP in neuronal survival (2003)](https://pubmed.ncbi.nlm.nih.gov/12652388/)

[Ye et al., CFLAR variants and cellular function (2001)](https://pubmed.ncbi.nlm.nih.gov/11278742/)

[Sprick et al., c-FLIP regulates death receptor signaling (2000)](https://pubmed.ncbi.nlm.nih.gov/10799127/)

[Micheau et al., NF-κB regulation of c-FLIP expression (2001)](https://pubmed.ncbi.nlm.nih.gov/11415818/)

[Obuser et al., c-FLIP in Alzheimer's disease neurons (2012)](https://pubmed.ncbi.nlm.nih.gov/22553033/)

[Pinaire et al., Targeting c-FLIP in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32867483/)

[Hacker et al., c-FLIP isoforms in cell death regulation (2009)](https://pubmed.ncbi.nlm.nih.gov/19007843/)

[Chang et al., Death receptor signaling in neurons (2006)](https://pubmed.ncbi.nlm.nih.gov/16531996/)

[Kokai et al., c-FLIP and necroptosis in PD models (2019)](https://pubmed.ncbi.nlm.nih.gov/30659264/)

[Liu et al., CFLAR polymorphisms and AD risk (2021)](https://pubmed.ncbi.nlm.nih.gov/34285242/)

[Wang et al., c-FLIP in cancer therapy (2007)](https://pubmed.ncbi.nlm.nih.gov/17213808/)

[Kirkbride et al., CFLAR in developmental cell death (2011)](https://pubmed.ncbi.nlm.nih.gov/21385653/)

[Ju et al., c-FLIP in neuroinflammation (2019)](https://pubmed.ncbi.nlm.nih.gov/30614563/)

[Song et al., c-FLIP and mitochondrial apoptosis (2017)](https://pubmed.ncbi.nlm.nih.gov/28287337/)

[Stehlik et al., c-FLIP isoforms differential regulation (2006)](https://pubmed.ncbi.nlm.nih.gov/16231015/)

[Yang et al., TRAIL-mediated signaling in neurons (2020)](https://pubmed.ncbi.nlm.nih.gov/32629378/)

[Zhou et al., c-FLIP in tau pathology (2022)](https://pubmed.ncbi.nlm.nih.gov/35178563/)

[Zhang et al., c-FLIP and amyloid-beta toxicity (2018)](https://pubmed.ncbi.nlm.nih.gov/29569389/)

[Morin et al., c-FLIP therapeutic modulation in AD (2019)](https://pubmed.ncbi.nlm.nih.gov/31075081/)

Pathway Diagram

The following diagram shows the key molecular relationships involving CFLAR discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

CFLAR

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-cflar
kg_node_id	CFLAR
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-68db84faa35d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-cflar'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

25%

Debates

0

Incoming

5

Outgoing

18

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CFLAR

CFLAR

CFLAR

Overview

Gene and Protein Structure

Gene Organization

Protein Isoforms

Structure-Function Relationships

Normal Function

Death Receptor Signaling

NF-κB Regulation

Regulation of Necroptosis

Expression in the Brain

Neuronal Expression Patterns

Regulation in Neurons

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Cancer (Dual Role)

Neurodevelopmental and Psychiatric Disorders

Mechanisms in Neurodegeneration

Apoptosis Inhibition

Cross-Talk with Mitochondrial Apoptosis

Neuroinflammation

TRAIL Signaling

Therapeutic Approaches

Targeting c-FLIP in Neurodegeneration

Challenges and Considerations

Biomarker Potential

Research Methods

Clinical Perspectives

Diagnostic and Therapeutic Considerations

Disease-Stage Specific Effects

Animal Models

Clinical Implications

Animal Models

Mouse Models

In Vitro Models

Zebrafish Models

Interaction Networks

Protein-Protein Interactions

Genetic Interactions

Future Research Directions

Unresolved Questions

Emerging Approaches

See Also

External Links

References

Pathway Diagram

💬 Discussion